While the use of chimeric antigen receptor (CAR) T-cell therapy has increased ... The most frequent of these immune-mediated ...

在在这项最新研究中，研究团队通过模拟异种移植组织排斥过程中快速且强烈的抗原加工和呈递，可利用暴露组织特异性抗体的异种细胞膜来源的囊泡将多肽抗原和 mRNA 编码抗原递送至树突状细胞（DC）。 在 黑色素 瘤小鼠和 胸腺瘤 ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer ...

Chimeric antigen receptor T-cell therapy has been really instrumental in how we treat patients with myeloma. It has really changed the face of how we treat this disease, so since 2021, we've had two ...

Our patients, they get CAR-T cells either in the hospital or outpatient. So, we either admit the patient for about 10 days, we give them the cells, you know, on the first day, their own cells. And ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Five patients had mild cytokine release syndrome that was effectively treated, and two patients experienced cystitis, which is irritation of the bladder. Unfortunately, the CAR-T cells did not ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

But some people are more likely to develop a toxic reaction to the illness, like the release of extra cytokines,” he explained ... chimeric antigen receptor (CAR) T-cell therapy — a cancer ...